International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea

References

• Barrett, J. S., Betourne, A., Walls, R. L., Lasater, K., Russell, S., Borens, A., Rohatagi, S., & Roddy, W. (2023). The future of rare disease drug development: The rare disease cures accelerator data analytics platform (RDCA-DAP). Journal of Pharmacokinetics and Pharmacodynamics, 50(6), 507–519. https://doi.org/10.1007/s10928-023-09859-7
   PubMed Web of Science ®Google Scholar
• Cavazzoni, P. (2022a, January). Advancing health through innovation: New drug therapy approvals 2021. Retrieved July 11, 2023, from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021
   Google Scholar
• Cavazzoni, P. (2022b). CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development. Retrieved July 11, 2023, from https://www.fda.gov/news-events/fda-voices/cder-continues-make-rare-diseases-priority-drug-approvals-and-programming-speed-therapeutic
   Google Scholar
• Center, K. L. I. (2018). Regulation on designation of orphan drugs. Retrieved July 6, 2023, from https://www.law.go.kr/admRulLsInfoP.do?chrClsCd=010202&admRulSeq=2100000128851
   Google Scholar
• Center, K. L. I. (2020). Rare disease management Act. Retrieved July 6, from https://www.law.go.kr/LSW//lsInfoP.do?lsiSeq=220907&ancYd=20200811&ancNo=17472&efYd=20200912&nwJoYnInfo=Y&efGubun=Y&chrClsCd=010202&ancYnChk=0#0000
   Google Scholar
• Cho, I., & Han, E. (2022). Drug lag and associated factors for approved drugs in Korea compared with the United States. International Journal of Environmental Research and Public Health, 19(5), 2857. https://doi.org/10.3390/ijerph19052857
   PubMed Web of Science ®Google Scholar
• Choi, H., Lee, H., Park, B., Kim, C., & Lee, J. (2023). Changes in the review period of drug application and a Drug Lag from the FDA and the EMA: An industry survey in South Korea between 2011 and 2020. Therapeutic Innovation & Regulatory Science, 57(3), 552–560. https://doi.org/10.1007/s43441-022-00486-x
   PubMed Web of Science ®Google Scholar
• CODE, U. S. (2023). 21 USC 379h: Authority to assess and use drug fees. Retrieved July 11, 2023, from https://uscode.house.gov/view.xhtml?req=(title:21%20section:379h%20edition:prelim)
   Google Scholar
• EMA. (2023a). Accelerated assessment. Retrieved July 11, 2023, from https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment
   Google Scholar
• EMA. (2023b). Committee for orphan medicinal products (COMP). Retrieved July 11, 2023, from https://www.ema.europa.eu/en/committees/committee-orphan-medicinal-products-comp
   Google Scholar
• EMA. (2023c). Orphan incentives. Retrieved July 11, 2023, from https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives
   Google Scholar
• EMA. (2023d). Rare disease (orphan) designations. Retrieved January 2, 2023, from https://www.ema.europa.eu/en/medicines/download-medicine-data#rare-disease-(orphan)-designations-section
   Google Scholar
• FDA. (2018). Framework for FDA’s real-world evidence program. Retrieved July 11, 2023, from https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
   Google Scholar
• FDA. (2022a). Designating an orphan product: Drugs and biological products. Retrieved July 11, 2023, from https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
   Google Scholar
• FDA. (2022b). Office of orphan products development. Retrieved July 11, 2023, from https://www.fda.gov/about-fda/office-clinical-policy-and-programs/office-orphan-products-development
   Google Scholar
• FDA. (2023a). Fast track, breakthrough therapy, accelerated approval, priority review. Retrieved July 11, 2023, from https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
   Google Scholar
• FDA. (2023b). Search orphan drug designations and approvals. Retrieved January 2, 2023, from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/?categoryctmspage9ctmspagectmspage0ctmspagectmspagectmspage0ctmspage0ctmspage%5Bctms%5D%5Bpage%5D=%3Fwtime%3D%7Bseek_to_s
   Google Scholar
• GAO, U. S. (2018, November). Orphan drugs: FDA could improve designation review consistency; Rare disease drug development challenges continue. Retrieved July 11, 2023, from https://www.gao.gov/products/gao-19-83
   Google Scholar
• GAO, U. S. (2020, January 31). Drug development: FDA's priority review voucher programs. Retrieved July 6, 2023, from https://www.gao.gov/products/gao-20-251
   Google Scholar
• Hadjivasiliou, M. S. A. (2022, April 27). Orphan drug report 2022: Niche no longer. Retrieved July 6, 2023, from https://www.evaluate.com/thought-leadership/pharma/orphan-drug-2022-report
   Google Scholar
• Harada, K., Toriyabe, K., & Ono, S. (2020). Survey of Japanese orphan drug program: Factors related to successful marketing approval. The Journal of Clinical Pharmacology, 60(1), 117–124. https://doi.org/10.1002/jcph.1501
   PubMed Web of Science ®Google Scholar
• Huang, Y. J., Chao, W. Y., Wang, C. C., & Chang, L. C. (2022). Orphan drug development: The impact of regulatory and reimbursement frameworks. Drug Discovery Today, 27(8), 1724–1732. https://doi.org/10.1016/j.drudis.2022.03.002
   PubMedGoogle Scholar
• Kim, E., & Kim, Y. (2018). Review of programs for improving patient’s access to medicines. Korean Journal of Clinical Pharmacy, 28(1), 40–50. https://doi.org/10.24304/kjcp.2018.28.1.40
   Google Scholar
• Lee, S. W., Park, S. H., Song, I., Noh, Y., Park, H., Ha, D., & Shin, J. Y. (2020). Notable differences in drug lag between Korea and Japan of new drugs between 2009 and 2017. Therapeutic Innovation & Regulatory Science, 54(2), 418–423. https://doi.org/10.1007/s43441-019-00071-9
   PubMed Web of Science ®Google Scholar
• Loorand-Stiver, L., Cowling, T., & Perras, C. (2013, October). Drugs for rare diseases: Evolving trends in regulatory and health technology assessment perspectives. Retrieved July 11, 2023, from https://www.cadth.ca/drugs-rare-diseases-evolving-trends-regulatory-and-health-technology-assessment-perspectives
   Google Scholar
• Maeda, K., Kaneko, M., Narukawa, M., & Arato, T. (2017). Points to consider: Efficacy and safety evaluations in the clinical development of ultra-orphan drugs. Orphanet Journal of Rare Diseases, 12(1), 143. https://doi.org/10.1186/s13023-017-0690-5
   PubMedGoogle Scholar
• MFDS. (2023a). Notification of orphan drug designation. Retrieved July 6, 2023, from https://www.mfds.go.kr/brd/m_76/list.do?page=2&srchFr=&srchTo=&srchWord=%ED%9D%AC%EA%B7%80%EC%9D%98%EC%95%BD%ED%92%88&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999
   Google Scholar
• MFDS. (2023b). Notification of partial revision of regulations on designation of orphan drugs. Retrieved July 6, 2023, from https://www.mfds.go.kr/brd/m_207/list.do?page=1&srchFr=&srchTo=&srchWord=%ED%9D%AC%EA%B7%80%EC%9D%98%EC%95%BD%ED%92%88&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999
   Google Scholar
• MFDS. (2023c). Search for information on medicines, etc. Retrieved July 6, 2023, from https://nedrug.mfds.go.kr/searchDrug
   Google Scholar
• MHLW. (2023). Overview of orphan drug/medical device designation system. Retrieved July 6, 2023, from https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html
   Google Scholar
• Miyazaki, T., Komiyama, M., Matsumaru, N., Maeda, H., & Tsukamoto, K. (2022). Lag time for new innovative, first-in-class, drug approval in Japan. Biological and Pharmaceutical Bulletin, 45(4), 477–482. https://doi.org/10.1248/bpb.b21-00898
   PubMed Web of Science ®Google Scholar
• Nagai, S. (2019). Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. International Journal of Molecular Sciences, 20(15), 3801. https://doi.org/10.3390/ijms20153801
   PubMed Web of Science ®Google Scholar
• Nagaraja, S., Balamuralidhara, V., Jyothi, M. S., & Ragunandhan, H. V. (2020). Orphan drug regulation In Japan and Australia. International Journal of Research in Pharmaceutical Sciences, 11(2), 1831–1839. https://doi.org/10.26452/ijrps.v11i2.2088
   Google Scholar
• NIBIOHN. (2022). List of orphan drug designated items. Retrieved May 27, 2023, from https://www.nibiohn.go.jp/nibio/part/promote/orphan_support/index.html#disclosure
   Google Scholar
• PMDA. (2023a). List of approved products. Retrieved May 1, from https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
   Google Scholar
• PMDA. (2023b). Unapproved drug database. Retrieved June 7, 2023, from https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0013.html
   Google Scholar
• Roberts, A. D., & Wadhwa, R. (2023). Orphan drug approval laws. StatPearls Publishing LLC. Retrieved July 11, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK572052/
   Google Scholar
• Rodriguez-Monguio, R., Spargo, T., & Seoane-Vazquez, E. (2017). Ethical imperatives of timely access to orphan drugs: Is possible to reconcile economic incentives and patients’ health needs? Orphanet Journal of Rare Diseases, 12(1), 1. https://doi.org/10.1186/s13023-016-0551-7
   PubMedGoogle Scholar
• Srivastava, G., & Winslow, A. (2019). Orphan drugs: Understanding the FDA approval process. https://doi.org/10.21428/b2e239dc.381f7d37
   Google Scholar
• Sujin Gwak, S. J. (2019, June 12). Analysis of domestic and foreign orphan drug market and R&D status. Retrieved July 11, 2023, from https://www.khidi.or.kr/board/view?pageNum=1&rowCnt=10&no1=319&linkId=48774874&menuId=MENU01783&maxIndex=00487748749998&minIndex=00001596099998&schType=0&schText=&schStartDate=&schEndDate=&boardStyle=&categoryId=&continent=&country
   Google Scholar
• Wellman-Labadie, O., & Zhou, Y. (2010). The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Health Policy, 95(2-3), 216–228. https://doi.org/10.1016/j.healthpol.2009.12.001
   PubMed Web of Science ®Google Scholar
• WHO. (2006). Public health, innovation and intellectual property rights. https://iris.who.int/bitstream/handle/10665/43460/a88438_eng.pdf?sequence=1
   Google Scholar